Maria-Cruz Morillo, Global Therapeutic Operations Lead, Allucent
Christopher Moxham, Chief Scientific Officer, Rarebase, PBC
Andrew Mumford, Managing Director, Initiate
Michael Murphy, Chief Medical & Scientific Officer, Worldwide Clinical Trials
Joseph Musumeci, President, BluePrint Orphan
Paul Nash, Senior Director, Simon-Kucher & Partners
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Indu Navar, Founder and Chief Executive Officer, EverythingALS
Amy Nicole Nayar, VP US Patient Advocacy and Government Affairs, Novartis Gene Therapies
Edward Neilan, Chief Medical and Scientific Officer, National Organization for Rare Disorders (NORD)
Robert Neusner, Director, Global Commercial Strategy,, Janssen Pharmaceutical companies of Johnson & Johnson
Amanda Nickles Fader, Professor of Gynecology and Obstetrics, Professor of Oncology, Vice-Chair, Gynecologic Surgical Operations,, Johns Hopkins Medical Center
Kris O’Brien, Executive Director, Program Strategy, Rare Disease and Pediatrics, Premier Research
Andrew Obenshain, Chief Executive Officer, Bluebird Bio
Matan Ofir, Director, Medison Ventures
Cristol O'Loughlin, Founder & Chief Executive Officer, ANGEL AID CARES
Charlene Son Rigby, Chief Executive Officer, RARE-X
Matt Sowards, Chief Innovation Officer, Scout Clinical
Violeta Stoyanova-Beninska, Chair of Committee for Orphan Medicinal Products, Medicines Evaluation Board, Medicines Evaluation Board
Swami Subramanian, Head, US/Global Pricing and Contracting, Regeneron
Dean Suhr, President, MLD Foundation
Jamie Sullivan, Director of Public Policy, EveryLife Foundation
Noreen Sullivan, Senior Principal, Value & Development Consulting, Evidera PPD
Web Sun, Co-Founder & President, Komodo Health
Lee Sutton, Vice President, Business Development, WEP Clinical
Tim Szymusiak, Head of Market Access Services, BluePrint Orphan
Mitra Tavakkoli, VP, Clinical Development, -
Amy Teets, Global Public Affairs Head, Pompe and MPS, Sanofi Genzyme
Ulrich Thienel, Chief Executive Officer, ReAlta Life Sciences
Michael Thomas, Principal, ZS
Kate Tighe, Head, US Public Affairs & Patient Advocacy - Rare Diseases, Sanofi Genzyme
Mark Trusheim, Strategic Director, MIT NEWDIGS
Andrew Udell, President of North America, Commercial, Calliditas Therapeutics
Fyodor Urnov, Scientific Director, Innovative Genomics Institute, Professor, Department of Molecular & Cell Biology, University of California, Berkeley
Zizi Uzezi Imatorbhebhe, Senior Vice President, Global Strategy and Development, Head Rare Disease Innovation Center,, Ergomed
Henri Vaitkevicius, VP of Clinical Development,, Marinus Pharmaceuticals
Kristin Van Goor, Lead, North America Regulatory Policy, Vertex Pharmaceuticals
Suneet Varma, Global President, Rare Disease Business Unit, Pfizer inc
Geeta Vemuri, Managing Partner, Agent Capital
Richard Vesely, Vice President, Regulatory Strategy,, Allucent
Erin Wade, Content Specialist, myTomorrows
Mary Wang, Science Policy Manager, Rare Diseases International
Dan Wasserstrom, Senior Director, Business Development, Clinigen Group
Christopher Watson, Director, Consulting, Thread Research
Kevin Weatherwax, Vice President, Head of Regulatory Affairs, WEP Clinical
Robert Weinstein, Division of Infectious Diseases, Rush University